Outcomes and endpoints in trials of cancer treatment: the past, present, and future
MK Wilson, K Karakasis, AM Oza - The Lancet Oncology, 2015 - thelancet.com
Cancer treatment should allow patients to live better or longer lives, and ideally, both. Trial
endpoints should show clinically meaningful improvements in patient survival or quality of …
endpoints should show clinically meaningful improvements in patient survival or quality of …
[HTML][HTML] Overcoming platinum and PARP-inhibitor resistance in ovarian cancer
M McMullen, K Karakasis, A Madariaga, AM Oza - Cancers, 2020 - mdpi.com
Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer
(OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as …
(OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as …
Outcomes and endpoints in cancer trials: bridging the divide
MK Wilson, D Collyar, DT Chingos… - The lancet …, 2015 - thelancet.com
Cancer is not one disease. Outcomes and endpoints in trials should incorporate the
therapeutic modality and cancer type because these factors affect clinician and patient …
therapeutic modality and cancer type because these factors affect clinician and patient …
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Summary Background The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have
shown preclinical synergy and promising activity in early phase clinical trials. We aimed to …
shown preclinical synergy and promising activity in early phase clinical trials. We aimed to …
Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus–related cervical carcinoma
S Lheureux, MO Butler, B Clarke, MC Cristea… - JAMA …, 2018 - jamanetwork.com
Importance Based on evidence of human papillomavirus (HPV)–induced immune evasion,
immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully …
immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully …
Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization
Purpose: Maintenance therapy with olaparib has improved progression-free survival in
women with high-grade serous ovarian cancer (HGSOC), particularly those harboring …
women with high-grade serous ovarian cancer (HGSOC), particularly those harboring …
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
Purpose Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor
olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 …
olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 …
EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression
Purpose: PARP inhibitors (PARPi) are standard-of-care therapy for high-grade serous
ovarian cancer (HGSOC). We investigated combining cediranib (antiangiogenic) with …
ovarian cancer (HGSOC). We investigated combining cediranib (antiangiogenic) with …
[HTML][HTML] Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long-and short-term survivors
Background Patients diagnosed with high-grade serous ovarian cancer (HGSOC) who
received initial debulking surgery followed by platinum-based chemotherapy can …
received initial debulking surgery followed by platinum-based chemotherapy can …
[HTML][HTML] Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery
Simple Summary Immune checkpoint inhibitors (ICIs) have been investigated in epithelial
ovarian cancer in first-line and recurrent settings. When used as a single agent or in …
ovarian cancer in first-line and recurrent settings. When used as a single agent or in …